Trump, AstraZeneca announce drug price cuts, $50B U.S. expansion

The agreement marks the second major pharma deal under Trump’s revived “Most Favoured Nation” (MFN) drug pricing policy.

Donald Trump / Instagram - @realdonaldtrump

President Donald Trump on Oct. 10 announced what he called a “historic achievement” to lower prescription drug prices for Americans, unveiling a partnership with AstraZeneca that ties medicine costs to the lowest global rates and commits the British drugmaker to invest $50 billion in the United States.

The agreement marks the second major pharma deal under Trump’s revived “Most Favoured Nation” (MFN) drug pricing policy, following a similar accord with Pfizer last week. It also underscores the administration’s bid to bring pharmaceutical manufacturing back to U.S. soil—a sharp turn from decades of reliance on global supply chains that stretch across India and China.

ALSO READ: Trump’s drug pricing push puts India’s pharma exports on notice

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login